69992-10-5

Basic information

• Product Name: 2'-DEOXY-3',5'-DI-O-ACETYLGUANOSINE
• Synonyms: 2'-DEOXY-3',5'-DI-O-ACETYLGUANOSINE;3',5'-DI-O-ACETYL-2'-DEOXYGUANOSINE;3',5'-Di-O-acetyl-2'-deoxy-D-guanosine;Nsc76761;2'-Deoxy-guanosine 3',5'-Diacetate;2'-Deoxyguanosine 3',5'-Diacetate;3',5'-Di-O-acetyldeoxyguanosine;3',5'-O-Diacetyl-2'-deoxyguanosine
• CAS NO: 69992-10-5
• Molecular Formula: C₁₄H₁₇N₅O₆
• Molecular Weight: 351.31
• Product Categories: Bases & Related Reagents;Nucleotides
• Mol File: 69992-10-5.mol
• Article Data: 27

Chemical Properties

• Melting Point: >300°C
• Boiling Point: 625.5°C at 760 mmHg
• Flash Point: 332.1°C
• Appearance: /
• Density: 1.72g/cm³
• Vapor Pressure: 1.46E-15mmHg at 25°C
• Refractive Index: 1.724
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 2'-DEOXY-3',5'-DI-O-ACETYLGUANOSINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-DEOXY-3',5'-DI-O-ACETYLGUANOSINE(69992-10-5)
• EPA Substance Registry System: 2'-DEOXY-3',5'-DI-O-ACETYLGUANOSINE(69992-10-5)

Safety Data

• Hazardous Substances Data: 69992-10-5(Hazardous Substances Data)

Usage

Chemical Properties

White Powder

Uses

2’-Deoxy-3’,5’-di-O-acetylguanosine reacts with hypobromous acid (HOBr) to form a major product, spiroiminodihydantoin.

InChI:InChI=1/C14H17N5O6/c1-6(20)23-4-9-8(24-7(2)21)3-10(25-9)19-5-16-11-12(19)17-14(15)18-13(11)22/h5,8-10H,3-4H2,1-2H3,(H3,15,17,18,22)

Upstream product

• 108-24-7 acetic anhydride 
• 961-07-9 2'-Deoxyguanosine 
• 763103-11-3 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-[2-amino-6-(2-trimethylsilanyl-ethoxy)-purin-9-yl]-tetrahydro-furan-3-yl ester 
• 961-07-9 2'-deoxyguanosine 
• 92447-23-9 6-O-(3,5-dichlorophenyl)-2-N-phenylacetyl-2'-deoxyguanosine 
• 763103-12-4 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-[6-(2-trimethylsilanyl-ethoxy)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-purin-9-yl]-tetrahydro-furan-3-yl ester 

Downstream Products

• 72560-68-0 5'-O-acetyl-2'-deoxyguanosine 
• 51549-58-7 2'-deoxy-3'-O-acetylguanosine 
• 119771-85-6 9-(3,5-di-O-acetyl-2-deoxy-β-D-erythro-pentofuranosyl)-2-amino-6-O-(2,4,6-triisopropylbenzenesulfonyl)purine 
• 108310-92-5 2-amino-6-(2-(p-nitrophenyl)ethyloxy)-9-[2'-deoxy-β-D-erythropentofuranosyl]purine diacetate 
• 78983-43-4 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-{2-[2-(4-tert-butyl-phenyl)-acetylamino]-6-oxo-1,6-dihydro-purin-9-yl}-tetrahydro-furan-3-yl ester 
• 78983-44-5 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-{2-[2-(4-tert-butyl-phenoxy)-acetylamino]-6-oxo-1,6-dihydro-purin-9-yl}-tetrahydro-furan-3-yl ester 
• 78983-40-1 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-[2-(4-chloro-benzoylamino)-6-oxo-1,6-dihydro-purin-9-yl]-tetrahydro-furan-3-yl ester 
• 78983-42-3 N-3,4-dichlorobenzoyl-3',5'-di-O-acetyl deoxyguanosine 
• 144640-75-5 3',5'-di-O-acetyl-O⁶-benzyl-2'-deoxyguanosine 
• 13389-03-2 8-bromo-2'-deoxyguanosine 
• 961-07-9 2'-Deoxyguanosine 
• 78983-41-2 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-[2-(4-nitro-benzoylamino)-6-oxo-1,6-dihydro-purin-9-yl]-tetrahydro-furan-3-yl ester 
• 705255-07-8 3',5'-di-O-acetyl-2'-deoxy-2-N-(mono-p-methoxytrityl)guanosine 
• 105821-12-3 3',5'-di-O-acetyl-2'-deoxy-2-N-(di-p-methoxytrityl)guanosine 

Relevant articles and documents

Discovery and mutagenicity of a guanidinoformimine lesion as a new intermediate of the oxidative deoxyguanosine degradation pathway

Oxidative degradation of DNA is a major mutagenic process. Reactive oxygen species (ROS) produced in the course of oxidative phosphorylation or by exogenous factors are known to attack preferentially deoxyguanosine. The latter decomposes to give mutagenic lesions, which under physiological conditions are efficiently repaired by specialized maintenance systems in the cell. Although many intermediates of the degradation pathway are today well-known, we report in this study the discovery of a new intermediate with an interesting guanidinoformimine structure. The structure elucidation of the new lesion was possible by using HPLC-MS techniques and organic synthesis. Finally we report the mutagenic potential of the new lesion in comparison to the known lesions imidazolone and oxazolone using primer extension and pyrosequencing experiments.

PHOSPHATE AND PHOSPHONATE BASED COMPOUNDS OF 6-THIO-2'-DEOXYGUANOSINE AS ANTI-CANCER AGENTS

Phosphates and phosphonates compounds of 6-thio-2'-deoxyguanosine are provided. The uses and pharmaceutical compositions of these compounds are disclosed.

6-disulfide-substituted-2'-deoxyguanosine compound and preparation method and application thereof

The invention provides a 6-disulfide-substituted-2'-deoxyguanosine compound and a preparation method thereof and an application thereof in an anti-tumor drug. The preparation method is capable of using 2'-deoxyguanosine as a structure mother nucleus, designing and synthesizing a series of brand-new thioredoxin-1(Trx-1) inhibitors. The compound is a structure as shown in a formula I, and Trx-1 activity inhibition testing is performed on the type of the compounds, apparent inhibitory activity is shown. It is indicated from in vitro and vivo research that these compounds show the remarkable tumorinhibitory effect to multiple types of tumor, can be applied to the drugs of the tumor related to human body cell proliferation, and provide a new way for the research of the anti-cancer drugs.

Synthesis of oligonucleotides carrying fluorescently labelled O6-alkylguanine for measuring hAGT activity

O6-alkylguanine-DNA-alkyltransferase (hAGT) activity provides resistance to cancer chemotherapeutic agents and its inhibition enhances chemotherapy. We herein present the development of a novel fluorescence assay for the detection of hAGT activity. We designed a dsDNA sequence containing a fluorophore-quencher pair, where the fluorophore was attached to an O6-benzylguanine. This precursor was synthesized using the Mitsunobu reaction to introduce the benzyl group. The alkyl-fluorophore group is transferred to the active site during the dealkylation, producing an increase in fluorescence which is correlated to hAGT activity. This assay can be used for the evaluation of potential inhibitors of hAGT in a straightforward manner.